Navigation Links
Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
Date:6/11/2009

llaborative relationship with world class investigators at OHRI. Jennerex oncolytic virus products are being manufactured in the "Mulcahy Manufacturing Unit" at OHRI, Ontario's first GMP facility dedicated to oncolytic virus production. Some of these development costs will be covered by the OICR grant. Some of the translational research funding will help support R&D, including human trials on Jennerex clinical candidates JX-594 and JX-929.

About the Ontario Institute for Cancer Research (OICR)

The OICR is dedicated to research in prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation.

About the Ottawa Hospital Research Institute

The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the University's Faculties of Medicine and Health Sciences. The OHRI includes more than 1,300 scientists, clinical investigators, graduate students, postdoctoral fellows, and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. www.ohri.ca

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-speci
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 The global ... basis of sectors, products & services and application. And ... with the increasing demand of advanced drugs for ... propel the growth for bioinformatics market. The implementation ... is known as bioinformatics. Decreasing cost of DNA ...
(Date:9/1/2015)... DUBLIN , Aug. 31, 2015 ... the addition of the "Introduction to Veterinary ... to their offering. This course ... a good introduction to those concerned with Veterinary ... experienced personnel who reqire a better understanding of ...
(Date:9/1/2015)... , Sept. 1, 2015  Abbott (NYSE: ABT ... a multi-center, randomized trial comparing the safety and effectiveness ... ® , Abbott,s market-leading, permanent drug eluting stent. ... Japan and enrolled 400 people with ... disease. The results will be featured at a late-breaking ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Introduction to Veterinary Pharmacovigilance Seminar (London, UK - September 23-24) 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4
... has released an updated AutoLabel solution with enhanced customized ... virtually 100% of medications have a scan-ready bar code ... AutoLabel is a complete barcoding solution that provides color-coded ... improve patient safety at the bedside. New features include ...
... ("CTI") (NASDAQ and MTA: CTIC) announced that final results ... relapsed or refractory acute myeloid leukemia ("AML") was selected ... of Hematology ("ASH") Annual Meeting, which will be held ... Jorge Cortes, M.D., of The University of ...
Cached Medicine Technology:Talyst Updates Its AutoLabel® Solution 2Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 2Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 3Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting 4
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... care delivery options, Blue Cross and Blue Shield of Minnesota (Blue Cross) has ... 2016. , Based in San Francisco, Doctor On Demand provides immediate access ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, to ... cancer patients. , Editorial and marketing groups within OncLive, which provides oncologists ...
(Date:9/1/2015)... San Francisco, Calif. (PRWEB) , ... September 01, ... ... services to corporations, law firms and government entities, announced today that it has ... as Senior Discovery Consultant. In this capacity, Sanderson will be responsible for ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... The ... and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection ... same mission – to raise awareness of the FSH Society and further FSHD research. ...
(Date:9/1/2015)... ... 01, 2015 , ... METTLER TOLEDO is pleased to announce ... Connectivity Kit, EasySampler data is automatically transferred to, and reported with, the referring ... platform. , EasySampler fully automates the sampling process including sampling capture, ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
... evidence of the damaging impact of marijuana on humans ... symptoms in some people, including hallucinations and paranoid delusions, ... recent study, one compound, cannabidiol, or CBD, made people ... tetrahydrocannabinol, or THC, produced temporary psychotic symptoms in people, ...
... victims of a bite from the Brazilian wandering spider (Phoneutria ... in blood pressure, they also sport an uncomfortable erection. ,And ... Viagras. Scientists say they have figured out the chemical that ... , “The erection is a side effect that everybody who ...
... healthcare scheme proposed by the Australian Federal government. The ... people to opt for private health insurance; yet this plan ... by public hospital, a report has shown. ,Dr ... Research on Health, explained the benefits of doing away with ...
... affect people of all ages. The general public is at ... instruction on ladder use and safety. ,According to ... Journal of Preventive Medicine and conducted by the Center for ... than 2.1 million individuals were treated in U.S. emergency departments ...
... suffer migraine attacks, beware. Recent research has shown the ... depression and suicidal tendencies. They could also be suffering ... ,Teens suffering migraines are prone to depressive tendencies ... such agonizing headaches, a new study has shown. ...
... homes have started coming to the fore. One among fifty ... review by the Department of Ageing, Disability and Home Care, ... involving abuse and lack of care. The main cause was ... carers. ,Advocates nationwide say it is a growing problem ...
Cached Medicine News:Health News:Marijuana can Trigger Psychotic Symptoms, New Study Finds 2Health News:Brazil Spider Offers Hope for Those Suffering from Erectile Dysfunction 2Health News:$3bn Rebate Scheme – Is Australia Making a Prudent Move 2Health News:Ladder-related Injuries on the Rise in U.S 2Health News:Link Between Migraine Attacks in Teens and Suicidal Tendencies 2Health News:Abuse of the Disabled in Government Run Homes 2
... ergonomic chairs with concave seats ... support • Select options like ... and glides. • BTT/1P chairs ... environments: industry, education, laboratory, clean ...
... with concave seats and standard-sized ... Select options like seats, backrests, ... • BTT/1P chairs are recommended ... education, laboratory, clean room, static ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
Medicine Products: